Welcome to Campus Sanofi UAE

An expert panel convened by EPOS2020 and EUFOREA proposed standardized definitions for disease control, remission, and progression in CRSwNP. This initiative aims to harmonize and optimize the standard of care for patients with CRSwNP.

This video presents results from the Phase 4 VESTIGE trial, demonstrating how dupilumab improves airway structure and function in severe type 2 asthma. Using breakthrough Functional Respiratory Imaging technology, the study reveals structural improvements that conventional lung function tests may not detect.

The management of bullous pemphigoid is challenging and new treatment approaches are needed. Read this article to find out more.

Systemic corticosteroids and other immunosuppressants are the current mainstay of therapy but carry risks for patients with bullous pemphigoid. Read this article to find out more

In bullous pemphigoid, autoimmunity to BP180 and BP230 is thought to trigger a type 2 inflammatory response. Read this article to find out more

Dr. Hany talks about the Focus on BP to Reduce CVD Risks.

Explore the compelling reasons why Praluent should be your first choice for patients with recent acute coronary syndrome who need to achieve their LDL-C goals. This informative video provides in-depth clinical insights and evidence, detailing how Praluent’s unique mechanism of action and proven efficacy can significantly improve patient outcomes. The video also covers tips on the 3 main factors: efficacy, safety, and administration to help you to integrate Praluent into your treatment plans. Enhance patient outcomes and elevate your practice with Praluent.